An amicus brief was filed by the Drug Policy Alliance on behalf of a wide array of New York State's and the nation's leading medical and substance abuse treatment authorities on Thursday, May 3, in New York federal appeals court challenging what may be the longest-ever federal prison sentence imposed for the simple possession of drugs for personal use behind bars. The unprecedented, nearly five-year prison sentence for simple drug possession was meted out last year to Cameron Douglas, son of actor Michael Douglas.
As reported yesterday by Jesse McKinley of The New York Times, Cameron Douglas who began abusing drugs at age 13 and who then got deeply hooked on heroin for many years, pled guilty in 2010 to participating in a drug distribution ring. He was sentenced to 60 months imprisonment for his conduct and remanded to federal prison where, despite his long-time problem with drug addiction, he was not given any drug treatment.
Last year Mr. Douglas relapsed on drugs while serving his prison sentence. He was caught with very small amounts of opioids for personal use, including a single dose of a medication used to treat heroin dependence that he had obtained without a prescription. Prison officials placed him in solitary confinement for 23 hours a day for 11 months and denied him social visits with family and friends.
But the federal district court which imposed Mr. Douglas his original 60-month sentence wasn't satisfied with these punishments, and nearly doubled Mr. Douglas' sentence for his drug relapse by adding an additional 54 months to Mr. Douglas' term.
Mr. Douglas' attorneys have now appealed his new (54-month) sentence, noting that it is significantly longer than any sentence imposed in modern legal history for simple drug possession behind bars, and arguing that the judges wrongly departed from the federal Sentencing Guidelines in imposing this excessive prison term.
Notably, a wide array of New York State's and the nation's leading medical and substance abuse treatment authorities are supporting Mr. Douglas' cause. The New York and California Societies of Addiction Medicine -- representing the two most prominent organizations of addiction specialists in the country -- and a host of other medical, public health and human rights organizations, along with prominent individual physicians and substance abuse researchers, filed a friend-of-the-court in support of Mr. Douglas' appeal.
In their brief, the medical experts contend that Mr. Douglas' drug relapse behind bars is not surprising, particularly given the fact that he, like so many other inmates suffering from addiction in American prisons and jails, are not provided any meaningful drug treatment during their incarceration.
The health experts claim that to sentence Mr. Douglas to an additional 54 months for his drug relapse -- particularly in the absence of treatment -- is not only counterproductive to Mr. Douglas' health and goals for recovery, but is, inhumane. They argue that such a sentence is futile both as a means of deterring drug use and obedience with the law, and that Mr. Douglas' medical conditions deserve adequate treatment, not incarceration sanctions.
"Tacking on more prison time for a person who is addicted to drugs because they relapse behind bars goes against fundamental principles of medicine, inflicts unnecessary suffering and undermines both safety and health," notes the brief's author, Daniel Abrahamson, director of legal affairs for the Drug Policy Alliance. "Such a response only fuels the vicious cycle we see daily across the country of drug-dependent persons being imprisoned while sick, coming out sicker, and then returning to jail even quicker -- at huge expense to everyone."
The experts note the lack of adequate drug treatment in the nation's prisons and jails, particularly for opioid-dependent persons, and urge corrections officials to remedy this situation as a critical step to breaking the cycle of addiction that affects the great majority of persons incarcerated in the U.S.
Never miss a thing. Sign up for up-to-the-minute breaking news alerts delivered straight to your inbox. Learn more